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To compare the effectiveness of individual support, group rehabilitation and a combination of the two in improving health-related
quality of life (HRQOL) and psychological well-being in cancer patients during 24 months after diagnosis, as compared with standard
care (SC). Furthermore, to compare the study sample and a random sample of the Swedish population with regard to HRQOL.
A total of 481 consecutive patients, newly diagnosed with cancer, were randomly assigned to one of the four alternatives. Data on
HRQOL and psychological well-being were collected at baseline and after 3, 6, 12 and 24 months. The interventions did not improve
HRQOL or psychological well-being, as compared with SC. At 3 months, the study sample reported an HRQOL comparable with
the normal population. Many cancer patients are able to manage their cancer-related concerns with the support available from SC.
However, it is reasonable to assume that the findings suffer from a lack of data from especially vulnerable patients and a possible
Hawthorne effect. It cannot be concluded that cancer patients have no need for additional psychosocial interventions. Future projects
should include screening and target interventions for those at risk for significant and prolonged psychological distress.
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Cancer and its treatment influence health-related quality of life
(HRQOL) in several domains, and the assessment of HRQOL is
crucial to efforts to improve clinical outcomes (Arndt et al, 2004;
Stanton et al, 2007). Many cancer patients experience psycho-
logical distress (Nordin and Glimelius, 1997; Burgess et al, 2005;
Korfage et al, 2006; Strong et al, 2007), and a relatively high
incidence of post-traumatic stress disorder symptoms has been
observed (Kangas et al, 2005). A large number of studies have
evaluated the effects of psychosocial interventions on psycho-
logical distress and HRQOL (van’t Spijker et al, 1997; Newell et al,
2002). However, it is still unclear whether individual or group
support is more effective in relieving problems of anxiety and
depression (Sheard and Maguire, 1999; Osborn et al, 2006).
Different types of interventions have been evaluated in different
diagnostic groups and at different times in the illness trajectory
(Arving et al, 2007; May et al, 2008), which makes it difficult to
assess the clinical value of the trial results. In addition, a majority
of the studies include small samples, which jeopardises the
possibilities of detecting small but clinically relevant differences
between groups.
Techniques from cognitive-behavioural therapy may be effective
in relieving psychological distress and treatment side effects in
cancer patients (Uitterhoeve et al, 2004; Osborn et al, 2006).
Methods such as distractions, relaxation and cognitive re-
structuring have been used to reduce, for example anxiety,
depression, nausea/vomiting and pain.
Involuntary weight loss is another well-recognised problem
affecting HRQOL in cancer patients (Persson et al, 2002). This
problem may be decreased through early nutritional assessment
and subsequent interventions for risk patients (Ravasco et al,
2005). Another important aspect of cancer care is the
co-ordination between different levels of the care system, to
improve continuity and reduce the patients’ need for emergency
and hospital care (Burge et al, 2003).
The Support-Care-Rehabilitation (SCR) project was carried out
between 1993 and 1997. The overall aim was to investigate whether
individual support begun at diagnosis or group support during the
rehabilitation period, or a combination of both, could help relieve
short- and long-term physical and psychosocial problems. Patients
were randomised among four groups in a 2 2 design: (1)
individual support (IS) starting immediately, (2) group rehabilita-
tion (GR), starting approximately 3 months after diagnosis, (3) a
combination of IS and GR (ISGR) and (4) standard care (SC). The
follow-up period was 24 months for all patients.
The aim of this study was to evaluate the effects of IS, GR and
ISGR on HRQOL and psychological well-being in cancer patients at
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A further aim was to compare the study sample and a random
sample of the Swedish population with regard to HRQOL.
MATERIALS AND METHODS
Patients
Consecutive patients with newly diagnosed (o3 months) prostate,
gastrointestinal (GI¼colorectal or gastric) or breast cancer were
included. In addition, women with a mammography finding
requiring surgery could also be included. Exclusion criteria were
the Karnofsky performance status o40, an earlier cancer
diagnosis, inability to communicate in Swedish and participation
in an ongoing randomised trial for patients with localised prostate
cancer (n¼59). Of 756 eligible patients, 73 (10%) were not
approached due to uncertainty about the diagnosis or adminis-
trative failure (Figure 1). A total of 202 patients (26%) rejected
participation. The most common reasons for this were ‘no interest’
(n¼80) and ‘too far to travel’ (n¼51). Patients who rejected
participation were older (mean: 71 years) than those who accepted
participation (mean: 62 years, Po0.001). This difference was
evident in all diagnostic groups. Of the 527 included patients, 42
were excluded due to a benign breast tumour at surgery. Four
patients were excluded due to an erroneous cancer diagnosis
(n¼2), senility (n¼1) or inclusion X3 months from diagnosis
(n¼1). Of all eligible patients, 223 (76%) with breast cancer, 140
(64%) with GI cancer (colorectal, n¼105 and gastric cancer,
n¼37) and 118 patients (49%) with prostate cancer were included.
Thus, of total 756 eligible patients, 481 (64%) agreed to participate,
using a procedure approved by the local Research Ethics
Committee (Figure 1).
A total of 142 (30%) patients did not complete the entire
24-month follow-up period (Figure 1). Seventy-two (51%) of those
died and 70 (49%) rejected further participation. Those who
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Figure 1 Participant flow.
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proportion with advanced disease (Advanced disease was GI
cancer with distant metastases (M1); prostate cancer with T-stage
4, lymph node and/or distant metastases (Nþ and/or M1) and
breast cancer with locally advanced cancer (T3–T4) and/or 47
positive axillary nodes or distant metastases (M1).), as compared
with those who remained in the project (mean age 67 years
compared with 63 years, Po0.001; advanced disease n¼64, 45%
compared with n¼46, 14%, Po0.001).
Randomisation
Randomisation was stratified for diagnosis and stage. Patients
were randomised by an independent oncologic centre (computer-
generated allocation schedule) to one of the four alternatives.
Colorectal and gastric cancer patients who had non-curable disease
(M1, short expected survival) were randomised between only IS
and SC (no rehabilitation condition). Thus, there was a higher
proportion of advanced GI cancer patients in IS and SC, as
compared with GR and ISGR (Table 1). With that exception, there
were no differences between treatment groups with regard to
baseline demographic and medical characteristics.
Interventions
All interventions have been described in detail elsewhere (Hellbom
et al, 1998; Johansson et al, 1999; Petersson et al, 2000; Persson
et al, 2002).
IS Individual support began as soon as possible after randomisa-
tion and consisted of individual psychological support, intensified
primary health care and nutritional support. All patients in IS were
contacted by a project psychologist (Hellbom et al, 1998). Current
problems identified jointly by the patient and the psychologist
were the focus of the intervention. Techniques used were derived
from cognitive behaviour therapy, including relaxation techniques,
identification and challenging of negative automatic thoughts and
activity scheduling and daily planning. If no problems were
identified, the contact was terminated, but the patient was
permitted to contact the psychologist when problems arise. Most
sessions were conducted face to face at the project agency.
However, a number of sessions were conducted by telephone
because of long travelling distances or disease- or treatment-
related problems. The median number of psychologist contacts
was 3 (minimum–maximum: 1–24). The psychologists in the
project received regular supervision throughout the study period.
Table 1 Baseline demographic and medical characteristics of the study sample, n¼481
ISGR, n¼117 IS, n¼134 GR, n¼104 SC, n¼126
n (%) n (%) n (%) n (%)
Age (years) mean (s.d.) 64.0 (13.2) 64.4 (12.6) 64.6 (13.5) 62.8 (13.0)
Gender
Female 73 (62) 77 (57) 55 (53) 72 (57)
Male 44 (38) 57 (43) 49 (47) 54 (43)
Breast cancer
a 60 (52) 61 (46) 51 (48) 51 (40)
T-stage
b
T1
c 40 (66) 42 (79) 36 (70) 41 (80)
T2 19 (32) 17 (28) 11 (22) 8 (16)
T3 1 (2) 1 (2) 2 (4) 0 (0)
N-stage
d
N0 30 (50) 36 (59) 36 (70) 31 (61)
N1 22 (37) 18 (30) 12 (24) 14 (27)
47 positive lymph nodes 4 (7) 3 (5) 3 (6) 3 (6)
Treatment in addition to surgery
Radiotherapy 53 (88) 52 (85) 43 (84) 46 (90)
Chemotherapy 18 (30) 16 (26) 9 (18) 10 (20)
Colorectal cancer 22 (19) 29 (22) 22 (21) 31 (25)
Dukes’ stage
A 1 (5) 4 (14) 0 (0) 5 (16)
B 12 (55) 10 (34) 13 (59) 11 (35)
C 8 (36) 6 (21) 8 (26) 7 (23)
D 1 (5) 9 (31) 1 (5) 8 (26)
Curative surgical resection
Yes 21 (95) 21 (72) 20 (91) 21 (68)
No 1 (5) 6 (21) 2 (9) 10 (32)
Not surgically treated
e 0 (0) 2 (7) 0 (0) 0 (0)
Treatments in addition to surgery
Radiotherapy 6 (27) 8 (28) 10 (45) 7 (23)
Chemotherapy 6 (27) 10 (34) 10 (45) 9 (29)
Gastric cancer 4 (3) 14 (10) 3 (3) 15 (12)
T-stage
b
1 0 (0) 2 (14) 0 (0) 2 (13)
2 1 (25) 3 (21) 1 (33) 2 (13)
3 1 (25) 0 (0) 0 (0) 1 (7)
4 0 (0) 1 (7) 0 (0) 1 (7)
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referred to the home care nurse in their neighbourhood
(Johansson et al, 1999, 2001). The patient’s general practitioner
(GP) was also informed about the cancer diagnosis and the referral
to the nurse. GPs and home care nurses received copies of the
medical records each time the patient was discharged from hospital
or had visited a specialist outpatient clinic. Education in cancer care
was arranged during the course of the trial for nurses and GPs. In
addition, GPs and home care nurses with patients randomised to IS
were offered supervision by a multi-professional oncology team.
Overall, 90% of IS patients reported home care nurse follow-up
contacts, as compared with 26% of non-IS patients.
Patients with GI cancer also received nutritional support (Persson
et al, 2002). A dietician made a dietary assessment including
calculation of the dietary intake as soon as possible after diagnosis.
After assessment, the dietician gave nutritional advice. When needed,
supplements and nutritional enrichment were prescribed. The next
assessment was scheduled 2–3 months later. Assessments were
conducted by telephone or face to face when the patient had a period
of in-patient care or visited the outpatient clinic.
GR Group rehabilitation started approximately 3 months after
randomisation and comprised 8 weekly sessions and a booster
session after 2 months (Petersson et al, 2000). The groups
consisted of 3–9 participants. Group rehabilitation implied that
the patient visited the project agency. A psychologist, physio-
therapist and oncology nurse conducted the meetings. Sessions
included cognitive behavioural techniques, light physical training
and relaxation. In two of the sessions, a physician presented
information about cancer and cancer treatment, and a dietician
provided dietary advice. All sessions offered opportunities to
disclose and discuss concerns with group leaders and members.
Overall, 80% of the patients participated in five or more sessions.
IS and GR Individual support and GR meant that the patients
received IS followed by GR. Individual psychological support was
(with few exceptions) terminated before GR began. A total of 132
(67%) of 196 invited patients participated in GR. A significantly
larger proportion of patients randomised to ISGR (42 out of 106)
declined GR participation as compared with patients randomised
to GR only (22 out of 90) (w
2¼5.10; d.f.¼1; Po0.05).
Standard care Standard care did not include regular follow-ups
by a dietician or medical social worker. However, the patients
could be referred to such services if the physician or the nurse
judged it necessary or if the patient made a specific request.
Table 1 (Continued)
ISGR, n¼117 IS, n¼134 GR, n¼104 SC, n¼126
n (%) n (%) n (%) n (%)
N-stage
d
0 0 (0) 3 (21) 1 (33) 2 (13)
1 4 (100) 3 (21) 0 (0) 3 (20)
M-stage
0 4 (100) 3 (21) 2 (67) 5 (33)
1 0 (0) 11 (79) 1 (33) 10 (67)
Curative surgical resection
Yes 4 (100) 3 (22) 1 (33) 3 (20)
No 0 (0) 9 (64) 2 (67) 9 (60)
Not surgically treated
e 0 (0) 2 (14) 0 (0) 3 20
Treatments in addition to surgery
Chemotherapy 2 (50) 4 (29) 0 (0) 7 (47)
Prostate cancer 30 (26) 30 9 29 (28) 29 (23)
T-stage
b
1 7 (23) 5 (17) 4 (14) 4 (14)
2 12 (40) 11 (37) 16 (55) 10 (34)
3 10 (33) 12 (40) 7 (24) 8 (28)
4 1 (3) 1 (3) 2 (7) 4 (14)
N-stage
d
0 5 (17) 5 (17) 9 (31) 10 (34)
1 2 (7) 5 (17) 3 (10) 3 (10)
M-stage
0 23 (77) 23 (77) 24 (83) 22 (76)
1 7 (23) 7 (23) 5 (17) 7 (24)
Primary treatment
Prostatectomy 2 (7) 2 (7) 6 (21) 4 (14)
Radiotherapy 3 (10) 6 (20) 3 (10) 7 (24)
Hormonal therapy 7 (23) 10 (33) 5 (17) 9 (31)
No primary treatment 18 (60) 12 (40) 15 (52) 9 (31)
Recurrence
f/progression
g during study period 20 (17) 16 (12) 13 (12) 14 (11)
Deceased during the study period 15 (13) 25 (19) 10 (10) 27 (21)
GR¼group rehabilitation; IS¼individual support; ISGR¼IS and GR; SC¼standard care.
aNo breast cancer patients had distant metastases at inclusion.
bT-stage undefined for 5
breast cancer, 21 gastric cancer and 5 prostate cancer patients.
cIncluding cancer in situ, n¼17.
dN-stage undefined for 24 breast cancer, 20 gastric cancer and 77 prostate cancer
patients.
ePatients with distant metastases.
fNine patients were affected by a new cancer.
gProgression for prostate cancer only.
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departments. Rehabilitation programmes or support groups were
not arranged. Referrals to home care nurses or GPs were rare, as
they usually are in routine care (Johansson et al, 1999).
Data collection
Background data Data on patients’ age, diagnosis, stage of
disease and treatment were collected from the medical records.
Points of assessments The patients completed the baseline
assessment before being informed about the randomisation result.
Subsequent assessments took place 3, 6, 12 and 24 months after
inclusion. The research nurse who informed the patients about the
project gave them the baseline questionnaires together with a
prepaid envelope. At subsequent assessments, the patients were
contacted by one of the investigators by phone. The investigator
gave instructions and then mailed the questionnaires, written
instructions and a prepaid envelope to the patient. Returned
questionnaires were checked for incomplete responses, and in such
cases the investigator contacted the patients by phone to complete
the questionnaire.
Questionnaires This study includes data from the well-known
questionnaires European Organization for Research and Treat-
ment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)
(version 1) (Aaronson et al, 1993; Fayers et al, 2001), the Hospital
Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983)
and the Impact of Event Scale (IES) (Horowitz et al, 1979). All
three were included at all points of assessment.
HRQOL in the Swedish population Normative data on EORTC
QLQ-C30 (Michelson et al, 2000) were used for the comparison of
HRQOL in the study sample and the Swedish population. The
EORTC QLQ-C30 was sent to 3919 adults and completed by 3069
(78%), 1619 (53%) women and 1450 (47%) men. The mean age for
both genders was 51.2 years.
Statistical analyses The statistical analyses were performed with
the SPSS v. 12.0.1. Substitution of missing values was made with
the mean of each patient’s responses, provided that at least half
of the subscale items had been completed (Fayers et al, 2001). A
one-way ANOVA with repeated measures was used to analyse the
effects of IS on HRQOL, anxiety, depression and post-traumatic
distress at 3 months. A two-way factorial ANOVA (IS/non-IS, and
GR/non-GR) with repeated measures was used to analyse
treatment-by-time interactions at 6, 12 and 24 months, using
3-month data as a second baseline. Patients with non-curable GI
cancer, who were not randomised to GR, were excluded from the
latter analyses. Pairwise comparisons, in case of statistically
significant main or interactions effects, were performed with a
Bonferroni correction. Additional analyses including age as a
covariate in all models were also conducted. However, they did not
yield differing results (data not presented). Power calculations
were undertaken using a power of 80% with a 0.05 two-sided
significance level. A sample size of 75 in each group was required
to detect a mean difference of 7.5 (s.d.¼23.0) in QLQ-C30
subscales. The corresponding values for the HADS anxiety or
depression were a sample size of 57 and a mean difference of 1.5
(s.d.¼4.0), and for the IES 72 in each group and mean difference
of 3 (s.d.¼9.0).
Differences in scores for the EORTC QLQ questionnaires from
baseline to the 24-month assessment were interpreted in terms of
clinical relevance, according to Osoba et al (1998), as small
(5–10p), moderate (11–19p) and large (420p) changes. Improve-
ments in levels of depression, anxiety and distress were interpreted
as the number with a lower level of problem according
to recommended cutoff scores for the HADS and the IES,
respectively. In addition, one-way ANOVA was performed to
assess initial differences between groups at baseline and 3 months,
and t-tests for the assessment of differences between participants
and dropouts.
Comparisons with normative HRQOL data were adjusted for
gender and age (Hjermstad et al, 1998). A one-sample t-test was
used to compare means between the study sample and the normal
population.
RESULTS
Patients who did not complete all five assessments (n¼142) had a
worse HRQOL at baseline compared with those who did. There
were differences with regard to the EORTC QLQ-C30 subscales
global health status, physical functioning, role functioning, social
functioning, fatigue, nausea and vomiting, pain, dyspnoea, appetite
loss, constipation and diarrhoea (mean differences¼3–13,
Po0.001 to o0.05), and with regard to the HAD Depression
subscale (means¼5.1 and 3.5, Po0.001).
Data on the EORTC QLQ-C30 at all points of assessments are
presented in Table 2 and data on the HADS and IES in Table 3.
There were no baseline differences between IS and SC. Group
rehabilitation patients had lower levels of constipation
(mean¼5.9, s.d.¼16.4) at 3 months as compared with non-GR
patients (mean¼10.7, s.d.¼23.5) (F¼5.4, d.f.¼1, P¼0.02).
Interaction effects
Role functioning improved from 3 to 6 and 12 months
(mean¼80.6, 82.2, 90.6; s.d.¼28.0, 29.3, 21.9) and deteriorated
slightly at 24 months (mean¼85.6, s.d.¼28.3) in GR patients,
whereas it improved at all points of assessment (mean¼85.4–88.1,
s.d.¼25.4–25.3) in non-GR patients (F¼2.7, d.f.¼3/954,
P¼0.045). However, there were no statistically significant
differences in the pairwise comparisons. Appetite loss decreased
from 3 to 6 months (mean¼5.1–3.7, s.d.¼14.2–11.1), worsened
at 12 months (mean¼5.8, s.d.¼16.0) and decreased again at 24
months (mean¼4.1, s.d.¼12.7) in GR patients, whereas it
improved from 3 to 6 and 12 months (mean¼8.1, 4.0, 2.4;
s.d.¼17.7, 12.6, 10.8) and worsened at 24 months (mean¼2.8,
s.d.¼10.7) in non-GR patients (F¼4.1, d.f.¼3/963, P¼0.007).
Pairwise comparisons revealed a statistically significant mean
difference between GR and non-GR patients at 12 months
(mean¼5.8 vs 2.4). There were no other treatment-by-time
interactions and no interaction effects of IS and GR.
Main effects of treatments
Individual support patients had a higher level of cognitive
functioning (mean¼87.4, s.d.¼14.2) as compared with non-IS
patients (mean¼84.0, s.d.¼16.4) (F¼4.6, d.f.¼1/321, P¼0.046)
from 3 to 24 months. There were no other main effects of
treatments.
Effect of time
The levels of problems were generally low with the exception of a
slightly deteriorated HRQOL at baseline, as compared with the
following points of assessment (Tables 2 and 3). Global quality of
life, emotional functioning, cognitive functioning, pain, insomnia,
appetite loss, anxiety, depression, intrusion and avoidance
improved from baseline to 3 months. Financial difficulties
worsened from baseline to 3 months. Global quality of life,
physical functioning, role functioning, emotional functioning,
social functioning, fatigue, nausea/vomiting, appetite loss, diar-
rhoea, financial difficulties, and depression improved from 3 to 24
months. Intrusion and avoidance improved from baseline to 3 and
HRQOL and distress in cancer patients
B Johansson et al
1979
British Journal of Cancer (2008) 99(12), 1975–1983 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sTable 2 Mean values (s.d.) for EORTC QLQ C-30 subscales for all groups (IS, n¼242–91; ISGR, n¼114–89; GR, n¼99–80; SC, n¼215–79) at five
points of assessment
Subscales Treatment Baseline 3 months Treatment 3 months 6 months 12 months 24 months Difference F (P-value)
a
Global health status (ql)
b,c IS 65 (23) 70 (22) IS 69 (23) 70 (20) 74 (20) 74 (17) S
ISGR 72 (21) 74 (20) 74 (21) 75 (19) S 1.0
SC 63 (23) 70 (20) GR 71 (19) 72 (19) 73 (19) 75 (19) M (0.4)
SC 69 (21) 71 (21) 70 (23) 74 (22) M
Physical functioning (pf)
c IS 83 (22) 83 (21) IS 84 (19) 84 (20) 84 (22) 85 (21)
ISGR 82 (22) 86 (19) 86 (20) 86 (20) 0.1
SC 81 (25) 83 (20) GR 82 (19) 87 (15) 88 (17) 87 (20) (0.9)
SC 84 (21) 83 (21) 86 (19) 85 (22)
Role functioning (rf)
c IS 80 (31) 80 (30) IS 82 (30) 83 (28) 87 (25) 86 (28) S
ISGR
d 78 (29) 82 (30) 87 (24) 84 (29) S 0.5
SC 78 (34) 82 (28) GR
d 83 (26) 82 (29) 92 (23) 88 (27) M (0.7)
SC 81 (29) 85 (28) 87 (25) 90 (23) M
Emotional functioning (ef)
b,c IS 74 (23) 84 (18) IS 83 (18) 83 (18) 85 (17) 87 (17) M
ISGR 84 (19) 86 (18) 87 (18) 87 (18) M 0.3
SC 75 (23) 82 (19) GR 83 (20) 85 (18) 85 (17) 86 (18) M (0.8)
SC 81 (19) 85 (19) 85 (17) 86 (20) M
Cognitive functioning (cf)
b IS 84 (20) 86 (18) IS
e 87 (19) 86 (19) 86 (15) 88 (16)
IS
e GR 86 (16) 87 (15) 87 (18) 88 (17) 0.3
SC 82 (21) 83 (19) GR 84 (18) 84 (20) 86 (18) 86 (19) (0.8)
SC 83 (19) 82 (19) 84 (19) 82 (20)
Social functioning (sf)
c IS 84 (24) 88 (20) IS 87 (20) 90 (17) 92 (15) 91 (18) S
ISGR 88 (20) 92 (16) 93 (16) 93 (15) S 0.9
SC 82 (25) 84 (23) GR 86 (21) 89 (20) 91 (17) 89 (20) S (0.4)
SC 82 (24) 86 (22) 91 (18) 90 (20) S
Fatigue (fa)
c IS 33 (27) 30 (24) IS 29 (24) 27 (24) 21 (22) 21 (22) M
ISGR 30 (24) 24 (24) 22 (22) 21 (21) S 0.6
SC 33 (26) 30 (24) GR 30 (21) 27 (23) 22 (21) 20 (20) S (0.6)
SC 31 (26) 26 (23) 23 (22) 22 (26) M
Nausea and vomiting (nv)
c IS 6 (13) 7 (15) IS 6 (13) 3 (10) 2 (7) 3 (9)
ISGR 7 (16) 3 (11) 3 (8) 2 (7) S 0.5
SC 6 (12) 6 (13) GR 5 (11) 3 (7) 2 (6) 3 (12) (0.7)
SC 6 (14) 4 (9) 3 (8) 3 (8)
Pain (pa)
b IS 24 (27) 17 (23) IS 18 (25) 17 (23) 17 (20) 15 (20) S
ISGR 15 (20) 14 (19) 17 (22) 13 (21) M 0.4
SC 23 (26) 18 (21) GR 18 (23) 16 (20) 15 (20) 12 (20) M (0.8)
SC 19 (19) 17 (22) 18 (23) 15 (23) M
Dyspnoea (dy) IS 17 (25) 18 (23) IS 19 (24) 23 (26) 18 (25) 19 (27)
ISGR 18 (21) 20 (25) 16 (23) 16 (23) 1.8
SC 17 (23) 18 (23) GR 18 (21) 15 (19) 19 (20) 15 (24) (0.1)
SC 19 (24) 21 (23) 16 (23) 17 (26)
Insomnia (sl)
b IS 27 (31) 20 (26) IS 21 (27) 24 (28) 19 (30) 18 (28) S
ISGR 19 (24) 19 (28) 18 (24) 18 (25) S 0.5
SC 27 (30) 23 (29) GR 22 (27) 16 (24) 20 (24) 16 (23) M (0.7)
SC 25 (31) 25 (31) 23 (31) 20 (27) S
Appetite loss (ap)
b,c IS 18 (30) 9 (20) IS 11 (21) 6 (15) 4 (15) 3 (10) M
ISGR
d 8 (19) 5 (14) 7 (20) 3 (11) M 0.3
SC 17 (28) 7 (18) GR
d 5 (14) 3 (9) 6 (14) 5 (14) M (0.8)
SC 10 (21) 6 (17) 5 (16) 4 (13) M
Constipation (co) IS 9 (23) 8 (19) IS 9 (20) 9 (19) 9 (19) 8 (19)
ISGR
f 7 (19) 8 (21) 9 (20) 9 (20) 1.0
SC 10 (23) 9 (21) GR
f 5 (14) 9 (19) 9 (18) 6 (17) (0.4)
SC 12 (26) 12 (23) 10 (24) 10 (24)
Diarrhoea (di)
c IS 10 (23) 10 (22) IS 11 (24) 6 (14) 5 (16) 4 (12) S
ISGR 9 (20) 6 (17) 5 (14) 7 (20) S 0.7
SC 11 (22) 10 (20) GR 9 (18) 7 (17) 6 (14) 6 (14) S (0.6)
SC 11 (22) 8 (19) 6 (16) 8 (17) S
Financial difficulties (fi)
c,g IS 5 (16) 8 (21) IS 9 (23) 6 (20) 5 (20) 5 (19)
ISGR 7 (20) 6 (15) 7 (17) 5 (14) 1.0
SC 6 (17) 12 (26) GR 9 (21) 7 (17) 5 (13) 5 (19) (0.4)
SC 14 (30) 13 (26) 11 (26) 7 (19) S
GR¼group rehabilitation; IS¼individual support; ISGR¼IS and GR; SC¼standard care. Statistically significant differences from baseline to 24 months (difference) are given as
small (S), moderate (M) or large (L).
aF and P-value for IS non-IS GR non-GR time interaction. d.f.¼3/954–963.
bImproved from baseline to 3 months (ql, ef, and
pa: Po0.001; sl: P¼0.012; cf: P¼0.04).
cImproved from 3 to 24 months (rf, sf, fa and nv: Po0.001; ql and di: P¼0.001; ef, ap and fi: P¼0.003; pf: P¼0.03).
dTime GR vs non-
GR interaction for rf (P¼0.045) and ap (P¼0.007).
eMain effect of IS at 3–24 months (P¼0.046).
fStatistically significant differences between GR patients and non-GR patients
at baseline, Po0.05.
gDeterioration from baseline to 3 months (Po0.001).
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s6 months, worsened at 12 months and improved again at 24
months. Pairwise comparisons revealed statistically significant
differences between the 12-month assessment and the baseline,
3-, 6- and 24-month assessments.
Comparison to HRQOL in the normal population
The study participants reported lower HRQOL than the
normal population at baseline (Table 4). However, the
differences in mean values were small, and at 3 months, the study
sample reported an HRQOL equal to that in the
normal population. It should also be noted that the study
participants reported less pain than the normal population at 3,
6, 12 and 24 months, and higher emotional functioning at 6, 12 and
24 months.
DISCUSSION
The interventions evaluated in the SCR project did not improve
newly diagnosed cancer patients’ HRQOL or psychological well-
being during a 24-month period after diagnosis, as compared with
standard care. There were only a few statistically significant
differences between treatment groups despite numerous analyses.
The scores of several HRQOL domains rapidly improved with
time, and at 3 months after diagnosis, the study sample reported
an HRQOL comparable with the normal population.
The sparse interaction and main effects of treatments were small
and inconclusive. However, the effects of time revealing an
improvement in psychological well-being, pain and global quality
of life (Tables 2 and 3) from baseline to 3 months in all treatment
groups correspond well with results from earlier studies. These
show, using the same measures that unscreened groups of cancer
Table 3 Mean values (s.d.) for HADS and IES for all groups (IS, n¼241-91; GR, n¼99-80; ISGR, n¼114-89; SC, n¼212-79) at five points of assessment
Treat Baseline 3 months Treatment 3 months 6 months 12 months 24 months Changed level F (P-value)
a
HADS
Anxiety
b IS 5 (5) 3 (4) IS 3 (3) 4 (3) 4 (4) 4 (4) 17
ISGR 4 (4) 3 (3) 3 (3) 3 (3) 17 1.6
SC 5 (5) 4 (4) GR 4 (4) 4 (4) 4 (4) 3 (4) 17 (0.2)
SC 4 (4) 4 (4) 4 (4) 3 (4) 24
Depression
b,c IS 4 (4) 3 (3) IS 3 (3) 3 (3) 3 (3) 3 (3) 10
ISGR 3 (3) 3 (3) 2 (3) 2 (3) 10 1.1
SC 4 (4) 3 (3) GR 3 (3) 3 (3) 3 (3) 2 (3) 6 (0.4)
SC 4 (4) 3 (4) 3 (3) 2 (3) 10
IES
Avoidance
b,d IS 14 (9) 11 (8) IS 10 (8) 11 (8) 16 (6) 10 (8) 30
ISGR 11 (9) 10 (9) 15 (5) 11 (10) 25 1.3
SC 15 (9) 12 (9) GR 12 (9) 10 (8) 15 (6) 10 (9) 29 (0.3)
SC 11 (8) 10 (9) 15 (5) 9 (8) 24
Intrusion
b,d IS 12 (8) 8 (7) IS 8 (7) 8 (7) 13 (5) 9 (7) 30 0.3
ISGR 8 (8) 7 (7) 12 (4) 8 (7) 29 (0.8)
SC 12 (8) 9 (7) GR 9 (7) 8 (7) 13 (4) 7 (6) 30
SC 8 (7) 7 (7) 12 (4) 8 (6) 29
GR¼group rehabilitation; HADS¼Hospital Anxiety and Depression Scale; IES¼Impact of Event Scale; IS¼individual support; ISGR¼IS and GR; SC¼standard care. Changed
level is the number of patients that changed level (improved) from baseline to 24 months according to recommended cutoff scores for the HADS and the IES
aFa n dP-value for
IS-non IS GR-non GR time interaction. d.f.¼3/954–963.
bImproved from baseline to 3 months, Po0.001.
cImproved from 3 to 6,12, and 24 months, P¼0.014.
dImproved
from 3 to 6 months, worsened at 12 and improved again at 24 months, Po0.001.
Table 4 Mean values for EORTC QLQ C-30 subscales in the normal population and in the study sample at all points of assessments
Subscales Reference data Baseline (n¼457) 3 months (n¼404) 6 months (n¼386) 12 months (n¼370) 24 months (n¼339)
Global health status 75 64
a M7 0
a S7 2
a 73
a 75
Physical functioning 85 82
a 83 85 86 86
Role functioning 85 79
a 81
a 83 88 87
b
Emotional functioning 83 75
a S8 3 8 5
b 85
b 86
b
Cognitive functioning 87 83
a 85
a 85
a 86 86
Social functioning 90 83
a S8 6
a 89 92
b 91
Fatigue 22 33
c M3 0
c S2 6
c 22 21
Nausea and vomiting 3 6
c 6
c 33 3
Pain 21 24
c 17
d 16
d S1 7
d 14
d S
Dyspnoea 18 17 18 20 17 17
Insomnia 18 27
c S2 2
c 21
c 20 18
Appetite loss 4 17
c M8
c S5 5 4
Constipation 6 10
c 8
c 9
c 9
c 8
Diarrhoea 5 10
c S1 0
c S7
c 66
Financial difficulties 7 5
d 10
c 87 6
Statistically significant differences given as small (S), moderate (M) or large (L)
aHigher (better) mean value in the normal population, P¼0.02–o0.001.
bLower (worse) mean
value in the normal population, P¼0.03–o0.001.
cLower (better) mean value in the normal population, P¼0.04–o0.001.
dHigher (worse) mean value in the normal
population, P¼o0.001.
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spatients go through, a period of relatively rapid improvement with
regard to HRQOL, including emotional functioning, after diagnosis
and medical treatment (Nordin and Glimelius, 1997, 1998; Arving
et al, 2007). Thus, the measures used in this study seem to be
capable of detecting statistically significant and clinically relevant
improvements with regard to these aspects.
Our results suggest that cancer patients generally manage to
handle cancer-related concerns and side effects with the support
available in standard care. However, several studies have shown
that a substantial minority of cancer patients report high levels of
distress and deteriorated HRQOL, which are not properly
diagnosed and attended to (Burgess et al, 2005; Korfage et al,
2006). Therefore, there are reasons to explore the validity of our
results. The following are noteworthy with regard to the external
validity: (1) patients who rejected participation were significantly
older than those who accepted participation, and (2) included
patients who did not complete all assessments were older and more
seriously diseased than those who completed the study. Patients
with an advanced disease are likely to suffer more from emotional
distress and deteriorated HRQOL and benefit from psychosocial
interventions (Uitterhoeve et al, 2004). High age in cancer patients
is associated with increased morbidity owing to concomitant
diseases and impaired physical, social and cognitive functions
(Extermann and Hurria, 2007). Hence, our results may suffer from
a lack of data from subgroups of especially vulnerable patients, and
the validity of our findings might thereby be limited to a group of
relatively well-functioning patients. This assumption is supported
by the presented data on HRQOL showing mainly improvements
over time with only one exception for financial difficulties, which
increased from baseline to 3 months, but improved again from 3 to
24 months.
When the SCR project was planned and initiated, the decision
was not to screen patients, as this was not recommended at the
time. On the contrary, great efforts were made to include as many
patients as possible in the studied diagnostic groups, which we also
succeeded in doing. However, the importance of screening to
identify patients with a need for psychosocial support and to target
interventions to such groups has been pointed out in several
reports during the past decade (Sheard and Maguire, 1999; Sharpe
et al, 2004). Thus, a recommendation for future projects aimed at
evaluating the effects of psychosocial support should be to include
screening and to target interventions only to those at risk for
significant distress. On the other hand, there is no current
consensus as to how to screen patients in need of an intervention
for prolonged emotional distress (Mitchell, 2007).
The project was comprised of extensive interventions with the
aim of maximising effects and increasing power. Individual
support included individual psychological support, intensified
primary health care and nutritional support for some patients, and
implied extra contact with at least 2–3 different professionals,
irrespective of the patients’ need for support. Group rehabilitation
comprised a total of nine sessions conducted by a psychologist,
physiotherapist and an oncology nurse. Both the individual
psychological support and GR implied a visit by the patient to
the SCR project agency, which for some patients was more than
100km away from home. The data collection was also extensive. In
addition to the measures included in the presented analysis,
patients were asked to complete the Courtauld Emotional Control
Scale (Watson and Greer, 1983) (baseline), the Miller Behavioural
Style Scale (Miller, 1995) (baseline), the Reaction to the Diagnosis
of Cancer Questionnaire (Frank-Stromborg, 1989) (baseline and 3
months), the Mental Adjustment to Cancer Scale (Watson et al,
1988) (all points of assessment), the Cancer Rehabilitation
Evaluation System Short Form (Schag et al, 1991) (3, 6, 12 and
24 months) and another 2–5 project-specific questionnaires
during the 24-month follow-up period. In total, the data collection
comprised 170–230 questions at each time of assessment. Thus,
there is a risk that our efforts to maximise and measure the effects
of the interventions meant that it was too strenuous for some
groups of patients, with a need of support, to complete
participation. This assumption is supported by the fact that older
patients tended to reject participation and did not respond to
questionnaires to the same extent as younger ones.
A possible Hawthorne effect should also be considered, as all
study participants were contacted by phone at each point of
assessment, to increase response rate and minimise missing data.
The participants were contacted before the questionnaires were
sent out, if they did not return them within in 2 weeks, and in cases
of missing data on returned questionnaires. Hence, project
participation may include numerous contacts with the project
group, also for those randomised to standard care.
Comparisons to reference data may also contain some
methodological difficulties (Hjermstad et al, 1998), that is the
EORTC QOL-C30 has been developed for oncological patients and
not for use in a normal population. However, it is widely
recognised that the use of population-based reference values is
relevant and provides an important aid in the interpretation of
QOL scales (Michelson et al, 2000; Fayers et al, 2001).
In conclusion, many cancer patients manage to handle cancer-
related concerns and side effects with the support available in
standard care. However, our findings seem to suffer from a lack of
data from especially vulnerable patients and from a possible
Hawthorne effect. Hence, it cannot be concluded that cancer
patients have no need of additional psychosocial interventions. It
is recommended that future projects include screening and target-
feasible interventions for those with the highest risks of significant
psychological distress.
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